Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRL3-ZUMAB in Advanced Solid Tumors and Haematologic Malignancies
NCT03191682Phase 1Active, not recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRL3-zumab in solid tumor, acute myeloid leukemia (AML) and multiple myeloma (MM), sponsored by National University Hospital. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Feb 2017; status: active, not recruiting.
02
Drugs
PRL3-zumab
03
Conditions
solid tumoracute myeloid leukemia (AML)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03191682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191682.